Navigation Links
Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease
Date:11/19/2007

PALO ALTO, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTCBB: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Drs. Steven Hersch and Diana Rosas presented results regarding the Company's novel Huntington's disease treatment candidate HD-02 at the 2007 World Congress on Huntington's Disease in Dresden, Germany.

Drs. Hersch and Rosas, of Massachusetts General Hospital, led the open- label, dose escalation study, which evaluated daily administration of HD-02 in doses ranging from 10 to 40 grams. Results of the study showed that a 30-gram dose provided the optimal levels of efficacy, safety, and tolerability. The researchers also observed a slower cognitive decline and a sustained reduction in brain atrophy at the 30-gram dose level. These findings demonstrate the disease-modifying potential of HD-02 and provided the rationale for a Phase III study to further evaluate its efficacy at the 30-gram dose.

Based on these findings, Dr. Hersch and the Huntington Study Group have designed a double-blind, placebo-controlled Phase III clinical trial to evaluate the 30-gram dose and its ability to slow functional decline. The trial will be sponsored by the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH). Enrollment is anticipated to begin in the second half of 2008.

"We are excited about the results of this HD-02 study in Huntington's disease and are pleased to have identified the optimal dose for further evaluation in next-year's Phase III trial," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena. "We are also pleased to further strengthen our relationship with the NIH via their sponsorship of this trial and look forward to working with the NCCAM within this organization to advance HD-02."

ABOUT HD-02

HD-02 is a novel drug candidate for the treatment of Hunti
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. U.S. Physicians Question Presidential Candidates
5. Schizophrenia candidate genes affect even healthy individuals
6. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
9. 1 in 5 bariatric surgery candidates not psychologically cleared for surgery
10. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Stevin McNamara’s original approach to guitar music is ... music that has existed in India for centuries. Literally meaning ... scale or some fixed sequence of notes, but is considered ... appropriate time of day or season of the year — ... musician occurs, in its turn creating an unique “sound manifestation” ...
(Date:8/21/2014)... Dotinga HealthDay Reporter THURSDAY, ... achieving orgasms during sex with a regular partner, straight ... study suggests. Using surveys of single people, the Kinsey ... climax about 85 percent of the time during sex, while ... females placed third, achieving orgasm during about 63 percent of ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... in treating respiratory syncytial virus (RSV), a leading cause of ... major progress in being able to treat human RSV infections ... second only to influenza virus," said study author Dr. John ... College of Medicine in Memphis. "There is no ...
(Date:8/21/2014)... The International and American Associations for Dental Research (IADR/AADR) ... Prevalence Following Five Decades of Decline." This study, by ... Chapel Hill, USA, follows edentulism (tooth loss) over the ... losing teeth and requiring dentures. It is published in ... Dental Research ( JDR ). , The ...
(Date:8/21/2014)... According to the new report “Waterborne Coatings ... PTFE, PVDF, PVDC, & Others), by Application (Architectural, ... & Others) - Global Forecast to 2019” published ... estimated to reach $77,838.71 Million by 2019. , ... spread through 225 Slides and in-depth TOC on ...
Breaking Medicine News(10 mins):Health News:Raga Cycle of Shakti Guitar Follows The Sun 2Health News:Raga Cycle of Shakti Guitar Follows The Sun 3Health News:Study: Men, Lesbians More Likely to Have Orgasms 2Health News:Study: Men, Lesbians More Likely to Have Orgasms 3Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Study shows steep decline in tooth loss, increase in socioeconomic disparities 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 4
... Hospital investigators have identified childhood cancer survivors who ... in part due to the lifesaving bone marrow ... underscore the need for long-term monitoring and early ... additional health education, researchers said. Among the measures ...
... of a screening urine dipstick to diagnose chronic kidney ... confirm Penn State College of Medicine researchers, who validated ... urine dipsticks have routinely been performed on healthy children ... Sekhar, M.D., assistant professor of pediatrics. "The AAP made ...
... of arthritis is greater for African Americans and Hispanics, ... Centers for Disease Control and Prevention (CDC) report published ... . According to the Arthritis Foundation, these findings suggest ... strategies aimed at arthritis prevention and management, particularly among ...
... ... Zoernack and the Socially Responsible (SRI) Bullion Fund Deploy Equity Long/Short Strategy ... by buying companies with good bottom up fundamentals and sell closely related ... minimizing correlation to the overall markets. In this case, we go long ...
... ... Conference, taking place in Houston, TX April 19, 20 and 21, 2010. Interaction ... Practices" and Best Practices in Learning and Development at Kaiser Permanente. , ... Cambridge, MA (PRWEB) April ...
... , ... launched its BodyTrace eScale and Website to the market. The world,s first GSM-enabled bathroom scale ... company,s web-scale and website represents a new milestone in Health 2.0 to promote the collaboration ... ...
Cached Medicine News:Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 2Health News:Research findings underscore needed action to safeguard lungs of young cancer survivors 3Health News:Routine screening for pediatric chronic kidney disease is not effective 2Health News:Minorities hit hardest by arthritis 2Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 2Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 3Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 4Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 5Health News:Steven Zoernack and The Bullion Fund Deploy Equity Long/Short Strategy with Apple (AAPL) and Research in Motion (RIMM) 6Health News:Interaction Associates to Sponsor HCI Talent Management for Health Care Conference 2Health News:Interaction Associates to Sponsor HCI Talent Management for Health Care Conference 3Health News:World's First GSM-Enabled Scale Gets Set for Launch to Help in Weight Loss 2
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  Henry Schein, Inc. ... health care products and services to office-based dental, animal health ... at two investor conferences in September: , September ... New York , NY at 12:50 p.m. ET , ... Conference in New York , NY at 1:25 ...
(Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
Breaking Medicine Technology:ScriptPro Achieves HITRUST Certification 2Henry Schein To Present At Two Investor Conferences In September 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
For the quantitative determination of Glycohemoglobin in blood....
For the quantitative determination of Glycohemoglobin (HbA1) in blood by,cation exchange resin. The test is to be used to monitor long-term glucose,control in diabetes mellitus....
... storage protein for iron. The ferritin molecule ... of heavy and light subunits, which surrounds ... phosphate [1]. Ferritin is synthesized in the ... with major concentrations found in the liver, ...
Rapid turn-around time, results in less than 4 hours...
Medicine Products: